PMID- 31051231
OWN - NLM
STAT- MEDLINE
DCOM- 20191202
LR  - 20191202
IS  - 1873-3476 (Electronic)
IS  - 0378-5173 (Linking)
VI  - 565
DP  - 2019 Jun 30
TI  - In vitro evaluation of innovative light-responsive nanoparticles for controlled 
      drug release in intestinal PDT.
PG  - 199-208
LID - S0378-5173(19)30348-5 [pii]
LID - 10.1016/j.ijpharm.2019.04.077 [doi]
AB  - Nanoparticles (NP) have gained importance as drug delivery systems for 
      pharmaceutical challenging drugs. Their size properties allow passive targeting 
      of cancer tissue by exploiting the enhanced permeability and retention (EPR) 
      effect. Furthermore, surface modifications enable an active drug targeting for 
      diseased regions in the human body. Besides the advantages, the drug release from 
      commonly used biodegradable NP is mostly depending on physiological 
      circumstances. Hence, there is a need for a more controllable drug release. The 
      use of light-responsive polymers is an innovative conception enabling a more 
      distinct drug release by an external light stimulus. The idea provides potential 
      for an increase in efficiency and safety of local therapies. In this study, 
      innovative light-sensitive NP were investigated for a photodynamic therapy (PDT) 
      of gastrointestinal tumors. Nanoparticles based on a newly developed 
      light-responsive polycarbonate (LrPC) and poly(lactic-co-glycolic-acid) (PLGA) 
      were loaded with the approved photosensitizer 
      5,10,15,20-tetrakis(m-hydroxyphenyl)chlorin (mTHPC). Mucus penetrating properties 
      were obtained by surface PEGylation of the nanoparticles either by using LrPC in 
      combination with a PEGylated PLA (PEG-PLA) or by a combination with PEGylated 
      LrPC (LrPC-PEG). Cytotoxic potential in dependency of a light-induced drug 
      release was investigated in different cytotoxicity assays. Intracellular 
      accumulation in mucus producing colon-carcinoma cell line HT-29-MTX was analysed 
      by HPLC and confocal laser microscopy.
CI  - Copyright (c) 2019 Elsevier B.V. All rights reserved.
FAU - Mahlert, Laura
AU  - Mahlert L
AD  - Institute of Pharmaceutical Technology and Biopharmacy, University of Muenster, 
      Corrensstrasse 48, 48149 Muenster, Germany. Electronic address: 
      l.mahlert@uni-muenster.de.
FAU - Anderski, Juliane
AU  - Anderski J
AD  - Institute of Pharmaceutical Technology and Biopharmacy, University of Muenster, 
      Corrensstrasse 48, 48149 Muenster, Germany. Electronic address: 
      j.anderski@uni-muenster.de.
FAU - Schoppa, Timo
AU  - Schoppa T
AD  - Institute of Pharmaceutical Technology and Biopharmacy, University of Muenster, 
      Corrensstrasse 48, 48149 Muenster, Germany. Electronic address: 
      schoppat@uni-muenster.de.
FAU - Mulac, Dennis
AU  - Mulac D
AD  - Institute of Pharmaceutical Technology and Biopharmacy, University of Muenster, 
      Corrensstrasse 48, 48149 Muenster, Germany. Electronic address: 
      mulac.dennis@uni-muenster.de.
FAU - Sun, Jingjiang
AU  - Sun J
AD  - Department of Chemistry, Paderborn University, Warburger Str. 100, 33098 
      Paderborn, Germany; Qingdao University of Science and Technology, School of 
      Polymer Science and Engineering, Zhengzhou Rd. 53, CN-266042 Qingdao, China. 
      Electronic address: sunjij@qust.edu.cn.
FAU - Kuckling, Dirk
AU  - Kuckling D
AD  - Department of Chemistry, Paderborn University, Warburger Str. 100, 33098 
      Paderborn, Germany. Electronic address: dirk.kuckling@uni-paderborn.de.
FAU - Langer, Klaus
AU  - Langer K
AD  - Institute of Pharmaceutical Technology and Biopharmacy, University of Muenster, 
      Corrensstrasse 48, 48149 Muenster, Germany. Electronic address: 
      k.langer@uni-muenster.de.
LA  - eng
PT  - Journal Article
DEP - 20190430
PL  - Netherlands
TA  - Int J Pharm
JT  - International journal of pharmaceutics
JID - 7804127
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Mesoporphyrins)
RN  - 0 (Photosensitizing Agents)
RN  - 0 (Polymers)
RN  - FU21S769PF (temoporfin)
SB  - IM
MH  - Cell Survival/drug effects
MH  - DNA Damage
MH  - Delayed-Action Preparations/administration & dosage/chemistry/radiation effects
MH  - HT29 Cells
MH  - Humans
MH  - Intestinal Neoplasms/*drug therapy
MH  - Light
MH  - *Mesoporphyrins/administration & dosage/chemistry/radiation effects
MH  - *Nanoparticles/administration & dosage/chemistry/radiation effects
MH  - *Photochemotherapy
MH  - *Photosensitizing Agents/administration & dosage/chemistry/radiation effects
MH  - Polymers/administration & dosage/chemistry/radiation effects
OTO - NOTNLM
OT  - Controlled drug delivery
OT  - HT-29-MTX cells
OT  - Intestinal cancer
OT  - Light-responsive polymers
OT  - Photodynamic therapy
EDAT- 2019/05/06 06:00
MHDA- 2019/12/04 06:00
CRDT- 2019/05/04 06:00
PHST- 2018/12/18 00:00 [received]
PHST- 2019/04/28 00:00 [revised]
PHST- 2019/04/29 00:00 [accepted]
PHST- 2019/05/06 06:00 [pubmed]
PHST- 2019/12/04 06:00 [medline]
PHST- 2019/05/04 06:00 [entrez]
AID - S0378-5173(19)30348-5 [pii]
AID - 10.1016/j.ijpharm.2019.04.077 [doi]
PST - ppublish
SO  - Int J Pharm. 2019 Jun 30;565:199-208. doi: 10.1016/j.ijpharm.2019.04.077. Epub 
      2019 Apr 30.